Cogent Biosciences is a publicly traded biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Positive results from registration-directed trials in NonAdvanced SM, Advanced SM and GIST were reported in 2025. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, KRAS and JAK2.
Oui — Cogent Biosciences a actuellement 11 offres ouvertes sur JobsRadar, réparties sur 16 services et 3 sites. 1 d’entre elles ont été publiées ces 30 derniers jours. 11 d’entre elles indiquent le salaire, avec une médiane de $200,000 par an et la plupart des offres entre $173,750 et $218,750. Dernière mise à jour le 5 septembre 2026 à 04:59 UTC.